gefitinib has been researched along with norbinaltorphimine in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (norbinaltorphimine) | Trials (norbinaltorphimine) | Recent Studies (post-2010) (norbinaltorphimine) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 918 | 0 | 205 |
| Protein | Taxonomy | gefitinib (IC50) | norbinaltorphimine (IC50) |
|---|---|---|---|
| Delta-type opioid receptor | Mus musculus (house mouse) | 0.0104 | |
| Kappa-type opioid receptor | Mus musculus (house mouse) | 0.0029 | |
| Mu-type opioid receptor | Homo sapiens (human) | 0.212 | |
| Delta-type opioid receptor | Homo sapiens (human) | 0.024 | |
| Kappa-type opioid receptor | Homo sapiens (human) | 0.0036 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hosoya, T; Imai, S; Kuzumaki, N; Morita, H; Nagasawa, A; Nagase, H; Narita, M; Okada, Y; Okano, H; Okano, HJ; Suzuki, A; Suzuki, T; Yamamizu, K; Yamashita, JK | 1 |
1 other study(ies) available for gefitinib and norbinaltorphimine
| Article | Year |
|---|---|
Effect of κ-opioid receptor agonist on the growth of non-small cell lung cancer (NSCLC) cells.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Mutation, Missense; Naltrexone; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Opioid, kappa; Signal Transduction; STAT3 Transcription Factor | 2012 |